USPTO Examiner COHEN MICHAEL P - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19186092TREATMENT OF IMMUNOSUPPRESSED SUBJECTSApril 2025June 2025Allow210NoNo
18808392TREATMENT OF IMMUNOSUPPRESSED SUBJECTSAugust 2024March 2025Allow710NoNo
18782666ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONSJuly 2024February 2025Allow610YesNo
18783305HYDROGEL FORMULATIONS AND METHODS AND DEVICES FOR ADMINISTRATION OF THE SAMEJuly 2024December 2024Allow500NoNo
18763543BIODEGRADABLE NANOCOMPOSITE SURGICAL SCREW CONTAINING BONE NANOPARTICLESJuly 2024May 2025Allow1001YesNo
18672534DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLSMay 2024September 2025Abandon1510NoNo
18662516METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSMay 2024April 2025Allow1110NoNo
18647232MICROBIAL INOCULANT COMPOSITIONS AND METHODSApril 2024October 2025Abandon1810NoNo
18631293POLYMER-ENCAPSULATED DRUG PARTICLESApril 2024January 2026Allow2110NoNo
18619502COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINEMarch 2024May 2025Allow1310NoNo
18594618COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODYMarch 2024November 2025Allow2101NoNo
18590455PROGAMMABLE POLYMERIC DRUGSFebruary 2024February 2026Allow2320NoNo
18423548BACTERICIDAL AND VIRUCIDAL PHARMACEUTICAL COMPOSITIONJanuary 2024August 2024Allow700NoNo
18416548Compositions for Treatment of Attention Deficit Hyperactivity DisorderJanuary 2024April 2025Allow1510YesNo
18406605SOIL APPLICATION OF CROP PROTECTION AGENTSJanuary 2024March 2025Abandon1501NoNo
18398070Prophylactic and Therapeutic Agents for Upper Respiratory Tract Infections Caused by Influenza and Other Enveloped VirusesDecember 2023March 2025Abandon1410NoNo
18396036METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATIONDecember 2023August 2025Abandon2011NoNo
18530533LEAVE-ON ORAL CARE COMPOSITIONSDecember 2023November 2024Allow1110NoNo
18519662METHOD OF MAKING GOLD NANOPARTICLES CAPPED WITH RESEDA ARABICA EXTRACT AND TREATMENT METHOD USING THE SAMENovember 2023February 2024Allow200YesNo
18517798COMPOSITION FOR PROMOTING HAIR GROWTH AND IMPROVING, PREVENTING, OR TREATING HAIR LOSS CONTAINING 2'-FUCOSYLLACTOSE AS AN ACTIVE INGREDIENTNovember 2023July 2024Allow810YesNo
18287463PREPARATION METHOD AND APPLICATION OF BIOMIMETIC NANO-PROTECTANT FOR DETOXIFYING DOX-INDUCED CARDIAC AND SYSTEMIC TOXICITYOctober 2023July 2024Allow910YesNo
18482952METHODS OF PROTECTING A PLANT FROM FUNGAL PESTSOctober 2023March 2026Allow2921NoNo
18470691HIGH-PURITY STEVIOL GLYCOSIDESSeptember 2023April 2025Allow1920NoNo
18448578CERAMIDE-LIKE LIPID-BASED DELIVERY VEHICLES AND USES THEREOFAugust 2023January 2025Allow1710NoNo
18232339METHOD OF DELIVERING PROTEINS INTO CELLSAugust 2023October 2025Allow2700NoNo
18365370METHODS OF PREPARING STEVIOL GLYCOSIDES AND USES OF THE SAMEAugust 2023April 2024Allow910NoNo
18361630POLY(AMINE-CO-ESTER) POLYMERS AND POLYPLEXES WITH MODIFIED END GROUPS AND METHODS OF USE THEREOFJuly 2023February 2024Allow700NoNo
18338052COPPER ION COMPOSITIONS AND METHODS OF TREATMENT FOR CONDITIONS CAUSED BY CORONAVIRUS AND INFLUENZAJune 2023February 2025Allow2020NoNo
18210381TREATMENT FOR GINGIVITISJune 2023October 2025Allow2830NoNo
18326293TREATMENT OF IMMUNOSUPPRESSED SUBJECTSMay 2023July 2024Allow1330YesNo
18324296USE OF PERILLA IN THE MANUFACTURE OF MEDICAMENT FOR INHIBITION OF COVID-19 VIRUSMay 2023February 2026Abandon3210NoNo
18322744Nucleic Acid-Based Therapy of Muscular DystrophiesMay 2023October 2024Abandon1710NoNo
18136553QUAT-FREE POWDERED DISINFECTANT/SANITIZERApril 2023December 2024Allow2020NoNo
18129073Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage FormsMarch 2023September 2024Allow1711NoNo
18126089LAMINATE SHEET FOR COSMETIC, AND COSMETIC SETMarch 2023December 2025Allow3310YesNo
18246062mRNA INDUCED EXPRESSION OF BONE MORPHOGENIC PROTEIN AND RECEPTOR AND METHODS RELATED THERETOMarch 2023December 2025Allow3310NoNo
18170229Nanoparticle/Peptide Method of Blocking Potassium ChannelsFebruary 2023December 2023Allow1000NoNo
18021020POROUS GLASS NANOPARTICLES AND DENTIN ADHESIVE COMPOSITION COMPRISING SAMEFebruary 2023September 2025Allow3110NoNo
18165398Oral Care Product and Methods of Use and Manufacture ThereofFebruary 2023September 2024Allow1920NoNo
18101974Method of Treating Hair Loss and Formulation for TreatmentJanuary 2023September 2024Allow1910NoNo
18005942NEW RHAMNOLIPID OLIGO-ESTERSJanuary 2023September 2025Allow3210NoNo
18083786Natural Preservatives and Antimicrobial Agents, Including Compositions ThereofDecember 2022July 2024Allow1910NoNo
18002241POLY(AMINE-CO-ESTER) POLYMERS WITH MODIFIED END GROUPS AND ENHANCED PULMONARY DELIVERYDecember 2022October 2025Allow3410YesNo
18079312COMPOSITION OF A THERAPEUTIC OLIGOMERDecember 2022February 2026Allow3811YesNo
18000339METHOD FOR GROWING PLANTSNovember 2022November 2025Allow3510NoNo
17973753Risk Mitigation of Infectious Disease Transmission from Incidental and Intimate Contact Using Atomic Scale Molecular Disruption and Biocidal Halo-fullerenes Delivered via Topical, Flushing and Enteral MechanismsOctober 2022February 2023Allow410YesNo
17973720METAL-MODIFIED NANOPARTICLE ENABLED DENTAL RESINS FOR PREVENTION OF DENTAL CARIESOctober 2022February 2026Abandon4011NoNo
17914952Targeted Poly(beta-amino ester)sSeptember 2022September 2025Allow3600NoNo
17914405STABLE AQUEOUS FORMULATION CONTAINING QUATERNARY AMMONIUM ORGANOSILANE HYDROLYSATE AND A METHOD FOR PREPARING SAMESeptember 2022October 2025Allow3710NoNo
17907029A METHOD OF ADMINISTERING A NANOPARTICLESeptember 2022May 2025Allow3100NoNo
17902617Oral Care Compositions and MethodsSeptember 2022June 2024Abandon2110NoNo
17897907FILAMENTS COMPRISING AN ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAMEAugust 2022March 2024Allow1810NoNo
17799805SUPPLEMENTED ANIMAL FEEDS FOR MAMMALSAugust 2022October 2025Abandon3801NoNo
178842413D PRINTING BIO GEL AND METHOD OF USEAugust 2022May 2025Allow3320YesNo
17883491METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSAugust 2022February 2024Allow1810NoNo
17852892CANNABINOID CHEWING GUM WITH HIGH INTENSITY SWEETENERSJune 2022December 2024Allow2930NoNo
17847604AQUEOUS COSMETIC COMPOSITIONS CONTAINING PELARGONIC ACID ESTERSJune 2022January 2024Allow1910NoNo
17787787ANTI-INFLAMMATORY DENDRIMER FORMULATION FOR THE TREATMENT OF PSORIASISJune 2022February 2026Allow4411NoNo
17756752PLATELET AGGREGATING AGENTJune 2022September 2025Abandon4010NoNo
17824602METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF SYNTHETIC LYSINE ANALOGS AND MIMETICSMay 2022October 2025Abandon4120NoYes
17745138D GLUTAMATE POLYGLUTAMATED ANTIFOLATES AND USES THEREOFMay 2022February 2025Allow3321NoNo
17776643CARBAZATE-ACTIVATED POLYVINYL ALCOHOL (PVAC) AS A POLYMER-BASED ANTITUMORAL AGENTMay 2022April 2025Allow3510NoNo
17738736PHOTOCURABLE REINFORCEMENT OF 3D PRINTED HYDROGEL OBJECTSMay 2022August 2025Allow3910YesNo
17767794FORMULATION OF INSECTICIDES COMPRISING GLYCOL ETHER SOLVENTSApril 2022September 2025Allow4210NoNo
17767325METHODS OF USING NANOPARTICLES AND MICROPARTICLES FOR THE DISRUPTION AND PREVENTION OF BIOFILMSApril 2022August 2025Allow4111NoNo
17713257COMPOSITION FOR HAIR REGENERATION COMPRISING MACROPHAGE-DERIVED EXTRACELLULAR VESICLE MIMETICSApril 2022March 2025Allow3621NoNo
17711643QUAT-FREE POWDERED DISINFECTANT/SANITIZERApril 2022October 2022Allow710YesNo
17711523FORMULATION FOR NASAL DELIVERY OF CANNABINOIDSApril 2022July 2024Abandon2720NoNo
17766060W/O/W EMULSION COMPOSITIONApril 2022April 2025Allow3610NoNo
17765357WATER-DISPERSION EMULSION COMPOSITION, METHOD FOR MANUFACTURING THE SAME, EMULSION ADDITION-CURED COMPOSITION, AND COSMETICMarch 2022August 2025Allow4111NoNo
17707425ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONSMarch 2022March 2026Allow4730NoNo
17642721ANTIMICROBIAL NANOWORMSMarch 2022December 2025Allow4521NoNo
17641651ULTRASOUND PHANTOMMarch 2022May 2025Abandon3810NoNo
17689314BRANCHED POLY(-AMINO ESTERS) FOR THE DELIVERY OF NUCLEIC ACIDSMarch 2022June 2025Allow3911NoNo
17679192CHEWABLE PHARMACEUTICAL DOSAGE FORMSFebruary 2022April 2025Allow3810NoNo
17637331METHOD FOR FACILITATING DELIVERY OF POISON BAIT TO WASP NESTFebruary 2022December 2025Allow4630YesNo
17675664BAKUCHIOL COMPOSITIONS FOR TREATMENT OF POST INFLAMMATORY HYPERPIGMENTATIONFebruary 2022October 2023Allow2010NoNo
17675931CAPSID THERAPYFebruary 2022January 2024Abandon2310NoNo
17666538ANTITUMOR APPLICATION OF POLYSACCHARIDE CARBON NANOGELSFebruary 2022January 2025Allow3610NoNo
17632179Compositions and Related MethodsFebruary 2022March 2025Allow3810NoNo
17565885HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURYDecember 2021April 2024Allow2810NoNo
17597270METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTSDecember 2021February 2026Abandon5021NoNo
17562871HYPOHALOUS ACIDS FOR TREATING INFLAMMATORY DISEASES AND INHIBITING GROWTH OF MALIGNANCIESDecember 2021October 2024Abandon3421NoNo
17557476Compositions for Treatment of Attention Deficit Hyperactivity DisorderDecember 2021April 2024Abandon2740NoNo
17557524Compositions for Treatment of Attention Deficit Hyperactivity DisorderDecember 2021October 2023Allow2220YesYes
17621147ORAL THIN FILMDecember 2021January 2026Allow4931NoNo
17554668LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASEDecember 2021June 2022Allow600YesNo
17552660COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR CANCER TREATMENT AND METABOLIC INTERVENTION THERAPYDecember 2021June 2024Abandon3011NoNo
17617540Highly dispersible zinc phthalocyanine-silica nanotubes and preparation method thereforDecember 2021December 2025Allow4811YesNo
17544196ALPHA AND GAMMA-D POLYGLUTAMATED PEMETREXED ANTIFOLATES AND USES THEREOFDecember 2021August 2024Allow3310NoNo
17544182POLYGLUTAMATED PEMETREXED AND USES THEREOFDecember 2021September 2024Allow3320NoNo
17544191ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOFDecember 2021August 2024Allow3210NoNo
17611865METHOD AND PROCEDURE FOR OBTAINING NATURAL PYRETHRIN MICROBIOCAPSULES WITH HIGH STABILITYNovember 2021September 2025Allow4611NoNo
17608648DEODORANT COMPOSITIONNovember 2021November 2024Allow3720NoNo
17513484BIOLOGICAL HAIR SHAPE CHANGE COMPOSITION AND KIT, AND METHOD FOR CHANGING HAIR SHAPEOctober 2021October 2024Allow3611YesNo
17605860METHOD FOR MANUFACTURING PHARMACEUTICAL PREPARATIONOctober 2021March 2025Abandon4001NoNo
17499348METHOD FOR MANUFACTURING MEDICATED CHEWING GUM WITHOUT COOLINGOctober 2021September 2025Abandon4730NoYes
17602932TOLEROGENIC ARTIFICIAL ANTIGEN-PRESENTING CELLSOctober 2021December 2025Allow5020NoNo
17602856TOLEROGENIC ARTIFICIAL ANTIGEN-PRESENTING CELLSOctober 2021July 2024Allow3311NoNo
17602162REMINERALIZING DENTAL MATERIALOctober 2021March 2026Allow5321NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COHEN, MICHAEL P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
15
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.0%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
60
Allowed After Appeal Filing
12
(20.0%)
Not Allowed After Appeal Filing
48
(80.0%)
Filing Benefit Percentile
24.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COHEN, MICHAEL P - Prosecution Strategy Guide

Executive Summary

Examiner COHEN, MICHAEL P works in Art Unit 1612 and has examined 831 patent applications in our dataset. With an allowance rate of 57.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner COHEN, MICHAEL P's allowance rate of 57.6% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by COHEN, MICHAEL P receive 2.17 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COHEN, MICHAEL P is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +28.5% benefit to allowance rate for applications examined by COHEN, MICHAEL P. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.8% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.8% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 64.3% of appeals filed. This is in the 44% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.9% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.